# Study of Magrolimab Combinations in Participants With Myeloid Malignancies

> **NCT04778410** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 54 (actual)

## Conditions studied

- Myeloid Malignancies

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** CC-486

## Key facts

- **NCT ID:** NCT04778410
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-28
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the study.
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04778410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04778410, "Study of Magrolimab Combinations in Participants With Myeloid Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04778410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*